{"title":"更正“使用抗血管生成药物提高抗肿瘤免疫:机制见解、当前进展和临床挑战”。","authors":"","doi":"10.1002/cac2.70060","DOIUrl":null,"url":null,"abstract":"<p>Shu-Jin Li<sup>1</sup>, Jia-Xian Chen<sup>1</sup>, Zhijun Sun<sup>1,2</sup></p><p><sup>1</sup>The State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei-MOST) & Key Laboratory of Oral Biomedicine, Ministry of Education, School and Hospital of Stomatology, Wuhan University, Wuhan 430079, Hubei, People's Republic of China</p><p><sup>2</sup>Department of Oral Maxillofacial-Head Neck Oncology, School and Hospital of Stomatology, Wuhan University, Wuhan 430079, Hubei, People's Republic of China</p><p>Shu-Jin Li and Jia-Xian Chen contributed equally to this work.</p><p><b>Correspondence</b>: Zhijun Sun (<span>[email protected]</span>)</p><p>Following the publication of this article [1], it has come to our attention that proper citations were inadvertently omitted when introducing the concept of “immunostimulatory vascular-modulating cycle” and its illustration in Figure 4. The concept was originally proposed by Khan and Kerbel (2018) [2].</p><p>The revised text now reads:</p><p>“<i>An immunostimulatory vascular-modulating cycle has been proposed to explain the synergistic effects observed between antiangiogenic agents and cancer immunotherapy, based on the mutual regulation between vascular normalization and immune responses</i> [2] (Figure 4).”</p><p>The revised Figure 4 is provided below:</p><p>We sincerely apologize for our mistake.</p><p>[1] Li SJ, Chen JX, Sun ZJ. Improving antitumor immunity using antiangiogenic agents: Mechanistic insights, current progress, and clinical challenges. Cancer Commun. 2021;41(9):830–50.</p><p>[2] Khan KA, Kerbel RS. Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa. Nat Rev Clin Oncol. 2018;15(5):310–24.</p>","PeriodicalId":9495,"journal":{"name":"Cancer Communications","volume":"45 10","pages":"1339-1340"},"PeriodicalIF":24.9000,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cac2.70060","citationCount":"0","resultStr":"{\"title\":\"Correction to “Improving antitumor immunity using antiangiogenic agents: Mechanistic insights, current progress, and clinical challenges”\",\"authors\":\"\",\"doi\":\"10.1002/cac2.70060\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Shu-Jin Li<sup>1</sup>, Jia-Xian Chen<sup>1</sup>, Zhijun Sun<sup>1,2</sup></p><p><sup>1</sup>The State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei-MOST) & Key Laboratory of Oral Biomedicine, Ministry of Education, School and Hospital of Stomatology, Wuhan University, Wuhan 430079, Hubei, People's Republic of China</p><p><sup>2</sup>Department of Oral Maxillofacial-Head Neck Oncology, School and Hospital of Stomatology, Wuhan University, Wuhan 430079, Hubei, People's Republic of China</p><p>Shu-Jin Li and Jia-Xian Chen contributed equally to this work.</p><p><b>Correspondence</b>: Zhijun Sun (<span>[email protected]</span>)</p><p>Following the publication of this article [1], it has come to our attention that proper citations were inadvertently omitted when introducing the concept of “immunostimulatory vascular-modulating cycle” and its illustration in Figure 4. The concept was originally proposed by Khan and Kerbel (2018) [2].</p><p>The revised text now reads:</p><p>“<i>An immunostimulatory vascular-modulating cycle has been proposed to explain the synergistic effects observed between antiangiogenic agents and cancer immunotherapy, based on the mutual regulation between vascular normalization and immune responses</i> [2] (Figure 4).”</p><p>The revised Figure 4 is provided below:</p><p>We sincerely apologize for our mistake.</p><p>[1] Li SJ, Chen JX, Sun ZJ. Improving antitumor immunity using antiangiogenic agents: Mechanistic insights, current progress, and clinical challenges. Cancer Commun. 2021;41(9):830–50.</p><p>[2] Khan KA, Kerbel RS. Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa. Nat Rev Clin Oncol. 2018;15(5):310–24.</p>\",\"PeriodicalId\":9495,\"journal\":{\"name\":\"Cancer Communications\",\"volume\":\"45 10\",\"pages\":\"1339-1340\"},\"PeriodicalIF\":24.9000,\"publicationDate\":\"2025-09-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cac2.70060\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Communications\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/cac2.70060\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Communications","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cac2.70060","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
武汉大学口腔医学院口腔生物医学教育部重点实验室,武汉430079;武汉大学口腔医学院口腔颌面头颈肿瘤科,武汉430079;中华人民共和国李淑瑾和陈家贤对这项工作作出了同样的贡献。在b[1]这篇文章发表后,我们注意到在介绍“免疫刺激血管调节周期”的概念及其图4中的说明时,无意中省略了适当的引用。这个概念最初是由Khan和Kerbel(2018)提出的。修订后的文本现在是:“基于血管正常化和免疫反应[2]之间的相互调节,已经提出了一个免疫刺激血管调节周期来解释抗血管生成药物和癌症免疫治疗之间观察到的协同效应(图4)。”修改后的图4如下:我们真诚地为我们的错误道歉。b[1]李士杰,陈建新,孙志军。使用抗血管生成药物提高抗肿瘤免疫:机制见解、当前进展和临床挑战。中华癌症杂志,2011;41(9):830-50Khan KA, Kerbel RS.抗血管生成治疗提高免疫治疗效果,反之亦然。中华疾病杂志,2018,15(5):310-24。
Correction to “Improving antitumor immunity using antiangiogenic agents: Mechanistic insights, current progress, and clinical challenges”
Shu-Jin Li1, Jia-Xian Chen1, Zhijun Sun1,2
1The State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei-MOST) & Key Laboratory of Oral Biomedicine, Ministry of Education, School and Hospital of Stomatology, Wuhan University, Wuhan 430079, Hubei, People's Republic of China
2Department of Oral Maxillofacial-Head Neck Oncology, School and Hospital of Stomatology, Wuhan University, Wuhan 430079, Hubei, People's Republic of China
Shu-Jin Li and Jia-Xian Chen contributed equally to this work.
Correspondence: Zhijun Sun ([email protected])
Following the publication of this article [1], it has come to our attention that proper citations were inadvertently omitted when introducing the concept of “immunostimulatory vascular-modulating cycle” and its illustration in Figure 4. The concept was originally proposed by Khan and Kerbel (2018) [2].
The revised text now reads:
“An immunostimulatory vascular-modulating cycle has been proposed to explain the synergistic effects observed between antiangiogenic agents and cancer immunotherapy, based on the mutual regulation between vascular normalization and immune responses [2] (Figure 4).”
The revised Figure 4 is provided below:
We sincerely apologize for our mistake.
[1] Li SJ, Chen JX, Sun ZJ. Improving antitumor immunity using antiangiogenic agents: Mechanistic insights, current progress, and clinical challenges. Cancer Commun. 2021;41(9):830–50.
[2] Khan KA, Kerbel RS. Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa. Nat Rev Clin Oncol. 2018;15(5):310–24.
期刊介绍:
Cancer Communications is an open access, peer-reviewed online journal that encompasses basic, clinical, and translational cancer research. The journal welcomes submissions concerning clinical trials, epidemiology, molecular and cellular biology, and genetics.